BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Marroquin CE, Marino G, Kuo PC, Plotkin JS, Rustgi VK, Lu AD, Edwards E, Taranto S, Johnson LB. Transplantation of hepatitis C-positive livers in hepatitis C-positive patients is equivalent to transplanting hepatitis C-negative livers. Liver Transpl. 2001;7:762-768. [PMID: 11552208 DOI: 10.1053/jlts.2001.27088] [Cited by in Crossref: 83] [Cited by in F6Publishing: 65] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Busuttil RW, Tanaka K. The utility of marginal donors in liver transplantation. Liver Transpl. 2003;9:651-663. [PMID: 12827549 DOI: 10.1053/jlts.2003.50105] [Cited by in Crossref: 494] [Cited by in F6Publishing: 424] [Article Influence: 26.0] [Reference Citation Analysis]
2 Mangus RS, Fridell JA, Vianna RM, Kwo PY, Chestovich P, Milgrom ML, Kazimi M, Hollinger EF, Read JT, Tector AJ. No difference in clinical transplant outcomes for local and imported liver allografts. Liver Transpl 2009;15:640-7. [DOI: 10.1002/lt.21726] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
3 Fondevila C, Jiménez-Galanes S, García-Valdecasas JC. [How can the number of liver transplantations be increased?]. Gastroenterol Hepatol 2009;32:519-30. [PMID: 19608299 DOI: 10.1016/j.gastrohep.2009.01.184] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
4 Delman AM, Ammann AM, Shah SA. The current status of virus-positive liver transplantation. Curr Opin Organ Transplant 2021;26:160-7. [PMID: 33595981 DOI: 10.1097/MOT.0000000000000850] [Reference Citation Analysis]
5 Massoud O. Hepatitis C: looking into the future. Expert Rev Gastroenterol Hepatol 2020;14:367-74. [PMID: 32216467 DOI: 10.1080/17474124.2020.1746641] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Saab S, Kardashian A, Saggi S, Choi G, Agopian V, Tong MJ. Use of hepatitis C-positive grafts in hepatitis C-negative liver transplant recipients is cost effective. Clin Transplant 2018;32:e13383. [PMID: 30129981 DOI: 10.1111/ctr.13383] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
7 Seem DL, Lee I, Umscheid CA, Kuehnert MJ; United States Public Health Service. PHS guideline for reducing human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission through organ transplantation. Public Health Rep 2013;128:247-343. [PMID: 23814319 DOI: 10.1177/003335491312800403] [Cited by in Crossref: 158] [Cited by in F6Publishing: 127] [Article Influence: 17.6] [Reference Citation Analysis]
8 Patwardhan VR, Curry MP. Reappraisal of the hepatitis C virus-positive donor in solid organ transplantation. Curr Opin Organ Transplant. 2015;20:267-275. [PMID: 25944236 DOI: 10.1097/mot.0000000000000191] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
9 Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol. 2017;14:203-217. [PMID: 28053342 DOI: 10.1038/nrgastro.2016.193] [Cited by in Crossref: 146] [Cited by in F6Publishing: 145] [Article Influence: 29.2] [Reference Citation Analysis]
10 Somerville L, Doucette K. Hepatitis C: Current Controversies and Future Potential in Solid Organ Transplantation. Curr Infect Dis Rep 2018;20:18. [PMID: 29789956 DOI: 10.1007/s11908-018-0625-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
11 Pezzati D, Ghinolfi D, De Simone P, Balzano E, Filipponi F. Strategies to optimize the use of marginal donors in liver transplantation. World J Hepatol 2015; 7(26): 2636-2647 [PMID: 26609341 DOI: 10.4254/wjh.v7.i26.2636] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
12 Bethea E, Arvind A, Gustafson J, Andersson K, Pratt D, Bhan I, Thiim M, Corey K, Bloom P, Markmann J, Yeh H, Elias N, Kimura S, Dageforde LA, Cuenca A, Kawai T, Safa K, Williams W, Gilligan H, Sise M, Fishman J, Kotton C, Kim A, Rogers CC, Shao S, Cote M, Irwin L, Myoung P, Chung RT. Immediate administration of antiviral therapy after transplantation of hepatitis C-infected livers into uninfected recipients: Implications for therapeutic planning. Am J Transplant. 2020;20:1619-1628. [PMID: 31887236 DOI: 10.1111/ajt.15768] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
13 Tuttle-newhall JE, Collins BH, Kuo PC, Schoeder R. Organ donation and treatment of the multi-organ donor. Current Problems in Surgery 2003;40:266-310. [DOI: 10.1067/msg.2003.120005] [Cited by in Crossref: 27] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
14 Stepanova M, Sayiner M, de Avila L, Younoszai Z, Racila A, Younossi ZM. Long-term outcomes of liver transplantation in patients with hepatitis C infection are not affected by HCV positivity of a donor. BMC Gastroenterol. 2016;16:137. [PMID: 27846801 DOI: 10.1186/s12876-016-0551-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
15 Hartwig MG, Patel V, Palmer SM, Cantu E, Appel JZ, Messier RH, Davis RD. Hepatitis B Core Antibody Positive Donors as a Safe and Effective Therapeutic Option to Increase Available Organs for Lung Transplantation: . Transplantation 2005;80:320-5. [DOI: 10.1097/01.tp.0000165858.86067.a2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
16 Teperman L. Donor-transmitted diseases. Liver Transpl 2010;16:S40-4. [DOI: 10.1002/lt.22153] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
17 Cameron A, Busuttil RW. AASLD/ILTS transplant course: Is there an extended donor suitable for everyone? Liver Transpl 2005;11:S2-5. [DOI: 10.1002/lt.20596] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 2.3] [Reference Citation Analysis]
18 Park H, Jung ES, Lee MH, Lee JM. Organ Donation from Donors with Hepatitis B or C in South Korea: A 2013-2017 Nationwide Data Analysis. Ann Transplant 2021;26:e928947. [PMID: 33927178 DOI: 10.12659/AOT.928947] [Reference Citation Analysis]
19 Abouna GM. Organ shortage crisis: problems and possible solutions. Transplant Proc. 2008;40:34-38. [PMID: 18261540 DOI: 10.1016/j.transproceed.2007.11.067] [Cited by in Crossref: 195] [Cited by in F6Publishing: 159] [Article Influence: 13.9] [Reference Citation Analysis]
20 Terrault NA, McCaughan GW, Curry MP, Gane E, Fagiuoli S, Fung JYY, Agarwal K, Lilly L, Strasser SI, Brown KA. International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates. Transplantation. 2017;101:945-955. [PMID: 28437387 DOI: 10.1097/tp.0000000000001708] [Cited by in Crossref: 57] [Cited by in F6Publishing: 12] [Article Influence: 14.3] [Reference Citation Analysis]
21 Rodriguez-luna H, Arenas J, Vargas HE. The use of virologically compromised organs in liver transplantation. Clinics in Liver Disease 2003;7:573-84. [DOI: 10.1016/s1089-3261(03)00056-4] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
22 Bushyhead D, Goldberg D. Use of Hepatitis C-Positive Donor Livers in Liver Transplantation. Curr Hepatol Rep 2017;16:12-7. [PMID: 28243573 DOI: 10.1007/s11901-017-0327-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
23 Abreu P, Gorgen A, Oldani G, Hibi T, Sapisochin G. Recent advances in liver transplantation for cancer: The future of transplant oncology. JHEP Rep 2019;1:377-91. [PMID: 32039389 DOI: 10.1016/j.jhepr.2019.07.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
24 Crismale JF, Ahmad J. Expanding the donor pool: Hepatitis C, hepatitis B and human immunodeficiency virus-positive donors in liver transplantation. World J Gastroenterol 2019; 25(47): 6799-6812 [PMID: 31885421 DOI: 10.3748/wjg.v25.i47.6799] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
25 Khapra AP, Agarwal K, Fiel MI, Kontorinis N, Hossain S, Emre S, Schiano TD. Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV+ allografts. Liver Transpl. 2006;12:1496-1503. [PMID: 16964597 DOI: 10.1002/lt.20849] [Cited by in Crossref: 80] [Cited by in F6Publishing: 62] [Article Influence: 5.3] [Reference Citation Analysis]
26 Filippidis P, Vionnet J, Manuel O, Mombelli M. Prevention of viral infections in solid organ transplant recipients in the era of COVID-19: a narrative review. Expert Rev Anti Infect Ther 2021;:1-18. [PMID: 34854329 DOI: 10.1080/14787210.2022.2013808] [Reference Citation Analysis]
27 Martin EF. Paradigm Shift in Utilization of Livers from Hepatitis C-Viremic Donors into Hepatitis C Virus-Negative Patients. Clin Liver Dis 2021;25:195-207. [PMID: 33978579 DOI: 10.1016/j.cld.2020.08.009] [Reference Citation Analysis]
28 Ramirez S, Perez-del-pulgar S, Carrion JA, Coto-llerena M, Mensa L, Dragun J, Garcia-valdecasas JC, Navasa M, Forns X. Hepatitis C virus superinfection of liver grafts: a detailed analysis of early exclusion of non-dominant virus strains. Journal of General Virology 2010;91:1183-8. [DOI: 10.1099/vir.0.018929-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
29 Ballarin R, Cucchetti A, Russo FP, Magistri P, Cescon M, Cillo U, Burra P, Pinna AD, Di Benedetto F. Long term follow-up and outcome of liver transplantation from hepatitis B surface antigen positive donors. World J Gastroenterol 2017; 23(12): 2095-2105 [PMID: 28405138 DOI: 10.3748/wjg.v23.i12.2095] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
30 Adair A, Powell J. Liver allografts from hepatitis C virus-positive donors may be transplanted with good outcome. World J Surg 2011;35:1596-7. [PMID: 21538189 DOI: 10.1007/s00268-011-1107-6] [Reference Citation Analysis]
31 Mueller NJ, Fishman JA. How should we evaluate organ donors with active or prior infections? Journal of Hepatology 2006;45:507-13. [DOI: 10.1016/j.jhep.2006.07.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
32 Roy A, Wang C, Li C, Lu L, Torbenson M, Hagedorn CH, Schwarz KB. Phenotypic and genotypic differences between a child with vertically acquired severe hepatitis C liver disease and his mother. J Pediatr Gastroenterol Nutr 2012;54:567-9. [PMID: 21716134 DOI: 10.1097/MPG.0b013e318229d96f] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
33 Kotloff RM, Blosser S, Fulda GJ, Malinoski D, Ahya VN, Angel L, Byrnes MC, DeVita MA, Grissom TE, Halpern SD. Management of the Potential Organ Donor in the ICU: Society of Critical Care Medicine/American College of Chest Physicians/Association of Organ Procurement Organizations Consensus Statement. Crit Care Med. 2015;43:1291-1325. [PMID: 25978154 DOI: 10.1097/ccm.0000000000000958] [Cited by in Crossref: 171] [Cited by in F6Publishing: 50] [Article Influence: 24.4] [Reference Citation Analysis]
34 Gallegos-orozco JF, Vargas HE, Rakela J. Virologically compromised donor grafts in liver transplantation. Journal of Hepatology 2004;41:512-21. [DOI: 10.1016/j.jhep.2004.08.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
35 Booth IA, Clark JE, LaMattina JC, Barth RN, Haririan A, Ravichandran BR. The Impact of Treatment Delay on Hepatitis C Liver Transplant Outcomes. J Pharm Pract 2021;:8971900211034261. [PMID: 34289722 DOI: 10.1177/08971900211034261] [Reference Citation Analysis]
36 Tector AJ, Mangus RS, Chestovich P, Vianna R, Fridell JA, Milgrom ML, Sanders C, Kwo PY. Use of extended criteria livers decreases wait time for liver transplantation without adversely impacting posttransplant survival. Ann Surg. 2006;244:439-450. [PMID: 16926570 DOI: 10.1097/01.sla.0000234896.18207.fa] [Cited by in Crossref: 56] [Cited by in F6Publishing: 71] [Article Influence: 3.5] [Reference Citation Analysis]
37 Harring TR, O’Mahony CA, Goss JA. Extended donors in liver transplantation. Clin Liver Dis. 2011;15:879-900. [PMID: 22032534 DOI: 10.1016/j.cld.2011.08.006] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
38 Sass DA, Reich DJ. Liver transplantation in the 21st century: expanding the donor options. Gastroenterol Clin North Am. 2011;40:641-658. [PMID: 21893278 DOI: 10.1016/j.gtc.2011.06.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
39 Arenas JI, Vargas HE, Rakela J. The use of hepatitis C-infected grafts in liver transplantation. Liver Transpl. 2003;9:S48-S51. [PMID: 14586895 DOI: 10.1053/jlts.2003.50252] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
40 Te H, Doucette K. Viral hepatitis: Guidelines by the American Society of Transplantation Infectious Disease Community of Practice. Clin Transplant 2019;33. [DOI: 10.1111/ctr.13514] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 7.7] [Reference Citation Analysis]
41 Shetty A, Buch A, Saab S. Use of Hepatitis C-Positive Liver Grafts in Hepatitis C-Negative Recipients. Dig Dis Sci 2019;64:1110-8. [PMID: 30560331 DOI: 10.1007/s10620-018-5404-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
42 Rosen HR. Hepatitis C in the liver transplant recipient: current understanding and treatment. Microbes and Infection 2002;4:1253-8. [DOI: 10.1016/s1286-4579(02)01653-2] [Cited by in Crossref: 10] [Article Influence: 0.5] [Reference Citation Analysis]
43 Gastaca M. Extended Criteria Donors in Liver Transplantation: Adapting Donor Quality and Recipient. Transplantation Proceedings 2009;41:975-9. [DOI: 10.1016/j.transproceed.2009.02.016] [Cited by in Crossref: 46] [Cited by in F6Publishing: 33] [Article Influence: 3.5] [Reference Citation Analysis]
44 Rowe IA, Wilde JT, Mutimer D. Is it justifiable to transplant infected livers into haemophilia recipients? Haemophilia 2012;18:685-7. [PMID: 22925332 DOI: 10.1111/j.1365-2516.2012.02801.x] [Reference Citation Analysis]
45 Gallegos-Orozco JF, Vargas HE. Should antihepatitis B virus core positive or antihepatitis C virus core positive subjects be accepted as organ donors for liver transplantation? J Clin Gastroenterol 2007;41:66-74. [PMID: 17198068 DOI: 10.1097/01.mcg.0000225636.60404.bf] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
46 Pratschke J, Mittler J, Neuhaus P. Ausweitung des Spenderpools unter Verwendung marginaler Organe. Chirurg 2008;79:130-4. [DOI: 10.1007/s00104-007-1458-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
47 Hidaka M, Takatsuki M, Soyama A, Miyaaki H, Ichikawa T, Nakao K, Kanematsu T, Eguchi S. Living donor liver transplantation from a donor previously treated with interferon for hepatitis C virus: a case report. J Med Case Rep 2011;5:276. [PMID: 21722402 DOI: 10.1186/1752-1947-5-276] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
48 Hashimoto K, Miller C. The use of marginal grafts in liver transplantation. J Hepatobiliary Pancreat Surg 2008;15:92-101. [DOI: 10.1007/s00534-007-1300-z] [Cited by in Crossref: 40] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
49 Foster R, Zimmerman M, Trotter JF. Expanding Donor Options: Marginal, Living, and Split Donors. Clinics in Liver Disease 2007;11:417-29. [DOI: 10.1016/j.cld.2007.04.004] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 3.0] [Reference Citation Analysis]
50 Saab S, Ghobrial RM, Ibrahim AB, Kunder G, Durazo F, Han S, Farmer DG, Yersiz H, Goldstein LI, Busuttil RW. Hepatitis C positive grafts may be used in orthotopic liver transplantation: a matched analysis. Am J Transplant. 2003;3:1167-1172. [PMID: 12919097 DOI: 10.1034/j.1600-6143.2003.00189.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 46] [Article Influence: 3.6] [Reference Citation Analysis]
51 Levitsky J, Formica RN, Bloom RD, Charlton M, Curry M, Friedewald J, Friedman J, Goldberg D, Hall S, Ison M, Kaiser T, Klassen D, Klintmalm G, Kobashigawa J, Liapakis A, O'Conner K, Reese P, Stewart D, Terrault N, Theodoropoulos N, Trotter J, Verna E, Volk M. The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation. Am J Transplant. 2017;17:2790-2802. [PMID: 28556422 DOI: 10.1111/ajt.14381] [Cited by in Crossref: 202] [Cited by in F6Publishing: 175] [Article Influence: 40.4] [Reference Citation Analysis]
52 Yao FY, Bass NM, Nikolai B, Davern TJ, Kerlan R, Wu V, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl. 2002;8:873-883. [PMID: 12360427 DOI: 10.1053/jlts.2002.34923] [Cited by in Crossref: 291] [Cited by in F6Publishing: 279] [Article Influence: 15.3] [Reference Citation Analysis]
53 Taylor R, Pietroski R, Hagan M, Eisenbrey A, Fontana R. Seropositive Abdominal and Thoracic Donor Organs Are Largely Underutilized. Transplantation Proceedings 2010;42:4479-87. [DOI: 10.1016/j.transproceed.2010.10.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
54 Northup PG, Argo CK, Nguyen DT, McBride MA, Kumer SC, Schmitt TM, Pruett TL. Liver allografts from hepatitis C positive donors can offer good outcomes in hepatitis C positive recipients: a US National Transplant Registry analysis. Transpl Int. 2010;23:1038-1044. [PMID: 20444239 DOI: 10.1111/j.1432-2277.2010.01092.x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 65] [Article Influence: 7.2] [Reference Citation Analysis]
55 Ciria R, Pleguezuelo M, Khorsandi SE, Davila D, Suddle A, Vilca-Melendez H, Rufian S, de la Mata M, Briceño J, Cillero PL, Heaton N. Strategies to reduce hepatitis C virus recurrence after liver transplantation. World J Hepatol 2013; 5(5): 237-250 [PMID: 23717735 DOI: 10.4254/wjh.v5.i5.237] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
56 Mitchell O, Gurakar A. Management of Hepatitis C Post-liver Transplantation: a Comprehensive Review. J Clin Transl Hepatol. 2015;3:140-148. [PMID: 26357641 DOI: 10.14218/jcth.2015.00005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
57 Reardon S. Hopeful act: A rebel transplants organs from HIV-positive donors. Nat Med 2014;20:1086-8. [DOI: 10.1038/nm1014-1086] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
58 deLemos AS, Schmeltzer PA, Russo MW. Recurrent hepatitis C after liver transplant. World J Gastroenterol 2014; 20(31): 10668-10681 [PMID: 25152571 DOI: 10.3748/wjg.v20.i31.10668] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
59 Coilly A, Samuel D. Pros and Cons: Usage of organs from donors infected with hepatitis C virus - Revision in the direct-acting antiviral era. J Hepatol. 2016;64:226-231. [PMID: 26375245 DOI: 10.1016/j.jhep.2015.09.002] [Cited by in Crossref: 44] [Cited by in F6Publishing: 34] [Article Influence: 6.3] [Reference Citation Analysis]
60 Verna EC, Brown RS. Hepatitis C and Liver Transplantation: Enhancing Outcomes and Should Patients Be Retransplanted. Clinics in Liver Disease 2008;12:637-59. [DOI: 10.1016/j.cld.2008.03.010] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
61 Nam H, Nilles KM, Levitsky J, Ison MG. Donor-derived Viral Infections in Liver Transplantation. Transplantation 2018;102:1824-36. [PMID: 29979345 DOI: 10.1097/TP.0000000000002326] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 3.3] [Reference Citation Analysis]
62 Salazar J, Saxena V, Kahn JG, Roberts JP, Mehta N, Volk M, Lai JC. Cost-Effectiveness of Direct-Acting Antiviral Treatment in Hepatitis C-Infected Liver Transplant Candidates With Compensated Cirrhosis and Hepatocellular Carcinoma. Transplantation 2017;101:1001-8. [PMID: 27926593 DOI: 10.1097/TP.0000000000001605] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
63 Terrault NA, Berenguer M. Treating hepatitis C infection in liver transplant recipients. Liver Transpl. 2006;12:1192-1204. [PMID: 16868944 DOI: 10.1002/lt.20865] [Cited by in Crossref: 100] [Cited by in F6Publishing: 82] [Article Influence: 6.7] [Reference Citation Analysis]
64 Routh D, Naidu S, Sharma S, Ranjan P, Godara R. Changing pattern of donor selection criteria in deceased donor liver transplant: a review of literature. J Clin Exp Hepatol. 2013;3:337-346. [PMID: 25755521 DOI: 10.1016/j.jceh.2013.11.007] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
65 Saab S, Chang AJ, Comulada S, Geevarghese SK, Anselmo RD, Durazo F, Han S, Farmer DG, Yersiz H, Goldstein LI. Outcomes of hepatitis C- and hepatitis B core antibody-positive grafts in orthotopic liver transplantation. Liver Transpl. 2003;9:1053-1061. [PMID: 14526400 DOI: 10.1053/jlts.2003.50208] [Cited by in Crossref: 54] [Cited by in F6Publishing: 43] [Article Influence: 3.0] [Reference Citation Analysis]
66 Ricchiuti A, Brunati A, Mirabella S, Pierini A, Franchello A, Salizzoni M. Use of Hepatitis C Virus-Positive Grafts in Liver Transplantation: A Single-Centre Experience. Transplantation Proceedings 2005;37:2569-70. [DOI: 10.1016/j.transproceed.2005.06.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
67 Kapila N, Khalloufi KA, Flocco G, Menon KVN, Lindenmeyer C, Reino D, Vanatta JM, Ebaid S, Tzakis A, Zervos XB. Transplantation of HCV Viremic Livers into HCV Viremic Recipients Followed by Direct-acting Antiviral Therapy. J Clin Transl Hepatol 2019;7:122-6. [PMID: 31293911 DOI: 10.14218/JCTH.2019.00014] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
68 Fondevila C. A bridge too far: We have not overstepped the line for extended deceased donors. Liver Transpl 2014;20 Suppl 2:S9-13. [PMID: 25220866 DOI: 10.1002/lt.24000] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]